A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

What this study is about

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Who can join (things the study team will check)

✅ You may be able to join if…

• Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year.
• Have moderate to severe disease not adequately controlled by topical treatments.
• Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.

🚫 You may not be able to join if…

• Have certain infections or other immune conditions.
• Recently used medications that could interfere with the study.
• Are pregnant or breastfeeding.

Where this trial is running

• Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute, Phoenix, Arizona, United States
• Skin Cancer and Dermatology Institute, Phoenix, Arizona, United States
• T. Joseph Raoof Md, Inc, Encino, California, United States
• Marvel Clinical Research, Huntington Beach, California, United States
• Antelope Valley Clinical Trials, Lancaster, California, United States
• Probity Medical Research, Los Angeles, California, United States
• NorCal Clinical Research, Rocklin, California, United States
• Focus Clinical Research, LLC -S, West Hills, California, United States
• Skin Care Research, Boca Raton, Florida, United States
• Florida Academic Dermatology Center Res and Edu, LLC, Coral Gables, Florida, United States
• Center for Skin Science and Innovation, Fort Lauderdale, Florida, United States
• Gsi Clinical Research, Margate, Florida, United States

+ 76 more sites.

Who to contact

Rob Eichelkraut · +1-214-728-6505 · Reichelkraut@bluefinbiomed.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07105488.